Lion Street Advisors, LLC Vertex Pharmaceuticals Inc Transaction History

Lion Street Advisors, LLC

$282 Million
Q3 2024

A detailed history of Lion Street Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Lion Street Advisors, LLC holds 570 shares of VRTX stock, worth $286,396. This represents 0.09% of its overall portfolio holdings.

Number of Shares

570

Previous 501 13.77%

Holding current value

$286,396

Previous $234,000 13.25%

% of portfolio

0.09%

Previous 0.09%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	BUY	$460.0 - $505.78 $31,740 - $34,898	69 Added 13.77%	570 $265,000
Q2 2024 Jul 12, 2024	SELL	$392.81 - $485.53 $49,886 - $61,662	-127 Reduced 20.22%	501 $234,000
Q4 2023 Jan 09, 2024	SELL	$343.0 - $410.68 $1,372 - $1,642	-4 Reduced 0.63%	628 $255,000
Q3 2023 Oct 19, 2023	SELL	$338.18 - $362.46 $292,525 - $313,527	-865 Reduced 57.78%	632 $219,000
Q2 2023 Jul 28, 2023	BUY	$314.42 - $351.91 $260,654 - $291,733	829 Added 124.1%	1,497 $526,000
Q1 2023 Apr 12, 2023	SELL	$283.23 - $323.1 $216,387 - $246,848	-764 Reduced 53.35%	668 $210,000
Q4 2022 Jan 19, 2023	BUY	$285.76 - $321.48 $409,208 - $460,359	1,432 New	1,432 $0
Q2 2022 Jul 19, 2022	BUY	$234.96 - $292.55 $36,888 - $45,930	157 Added 12.31%	1,432 $263,000
Q1 2022 May 10, 2022	SELL	$221.42 - $260.97 $41,848 - $49,323	-189 Reduced 12.91%	1,275 $332,000
Q4 2021 Jan 20, 2022	BUY	$177.01 - $223.45 $5,664 - $7,150	32 Added 2.23%	1,464 $322,000
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $259,750 - $290,681	1,432 New	1,432 $261,000
Q2 2020 Jul 20, 2020	SELL	$225.48 - $295.8 $3,382 - $4,437	-15 Closed	0 $0
Q1 2020 May 06, 2020	BUY	$199.77 - $247.81 $2,996 - $3,717	15 New	15 $4,000

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lion Street Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lion Street Advisors, LLC with notifications on news.

Account

Lion Street Advisors, LLC Vertex Pharmaceuticals Inc Transaction History